Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development. It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications. The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific DDR inhibitor with key and expert opinion points reinforcing the most important concepts detailed to enable the reader to develop a deep understanding of the topic. Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis.

Oncology. --- Medical radiology. --- Pharmacology. --- Radiation Oncology. --- DNA Repair. --- Neoplasms --- Poly(ADP-ribose) Polymerase Inhibitors. --- DNA Repair Enzymes. --- therapy.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges.

Technology: general issues --- History of engineering & technology --- microtubule acetylation --- triple-negative breast cancer --- anti-cancer agent --- apoptosis --- K562 --- 8-hydroxydaidzein --- autophagy --- BCR-ABL --- MAPK --- NF-κB --- c-myc --- RNA interference --- siRNA --- oncogene --- gene silencing --- expression --- nanosystems --- Cytochrome P450 --- CYP1A1 --- CYP1B1 --- CYP2W1 --- breast cancer --- prodrug --- bioprecursor --- duocarmycin --- phortress --- AQ4N --- 5-FU resistance --- colorectal cancer --- drug repurposing --- Genomics of Drug Sensitivity in Cancer --- Connectivity Map --- anticancer drug --- B-lactam steroid alkylators --- synthetic lethality --- poly (ADP-ribose) polymerase inhibitors --- ovarian cancer --- hybrid steroidal alkylating agents --- migration --- invasion --- glioblastoma --- CCN1 --- mesenchymal–amoeboid transition --- biomarker --- HepG2 --- Huh7 --- isatin sulfonamides --- angiogenesis --- cancer hallmarks --- molecular docking --- EGFR tyrosine kinase inhibitor --- photon upconversion --- triplet-triplet annihilation --- in vivo imaging --- PLGA --- nanoparticles --- affibody molecule --- human epidermal growth factor receptor 3 (HER3) --- BxPC-3 --- emtansine --- DM1 --- albumin binding domain --- affibody drug conjugate (AffiDC) --- n/a --- mesenchymal-amoeboid transition